- Home
- RXRX vs NAD Comparison
RXRX vs NAD Comparison
Compare RXRX & NAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RXRX | NAD |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RXRX | NAD |
|---|---|---|
| Price | $3.47 | $12.21 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 21.9M | 595.7K |
| Earning Date | 02-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.35% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,689,000.00 | N/A |
| Revenue This Year | $6.74 | N/A |
| Revenue Next Year | $34.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.45 | $9.56 |
| 52 Week High | $12.36 | $11.64 |
Technical Indicators
Market Signals| Indicator | RXRX | NAD |
|---|---|---|
| Relative Strength Index (RSI) | 33.33 | 61.23 |
| Support Level | $3.54 | $11.97 |
| Resistance Level | $4.09 | $12.24 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 3.10 | 97.30 |
Price Performance
Historical ComparisonAbout RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About NAD Nuveen Quality Municipal Income Fund
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.